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Introduction
The COVID-19 pandemic has placed unprecedented 
strains on our medical system as specialties have had 
to reconsider “essential” in-person services and find 
novel ways to remotely ensure continuity of care. One 
such modality of care includes telehealth services, which 
have experienced a rapid rise in utility with a reported 
4,347% increase in telehealth visits from March 2019 to 
March 2020 [1]. Although used for decades, telemedicine 
has historically been limited by reimbursement, as well 
as systems adoption and maintenance costs. Physical 
distancing measures throughout the pandemic, however, 
necessitated essentially overnight adoption of insurance 
coverage in both public and private sectors. Dermatology 
is among the earliest and most well-suited specialties to 
adopt telemedicine given the visual nature of the specialty 
[2]. Since the onset of the COVID-19 pandemic, we 
have seen a radical uptake of teledermatology services 
across the nation. In this paper, we review the literature 
published to date highlighting the state of teledermatology 
prior to the pandemic, the policy changes that facilitated 
the rapid expansion of teledermatology services during the 
pandemic, and the impact this has had on our dermatologic 
practices now and moving forward.
Discussion
Teledermatology services can be delivered through two 
primary modalities: store-and-forward (SAF) technology, 
which entails transmission of images to a provider for 
review in an asynchronous manner, or live interactions, 
Abstract
Since the onset of the COVID-19 pandemic, telemedicine has rapidly expanded across the nation as medical systems have had to 
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including video visits or audio call [3]. Benefits of SAF 
teledermatology include greater image resolution and 
patient convenience as appointment times are not 
required. Alternatively, live video visits permit the 
clinician to view lesions in real time from different angles 
and allow for direct patient-provider interactions. While 
this modality allows patients to interact directly with their 
providers, it does necessitate the presence of high-speed 
internet access [4]. 
The diagnostic and treatment accuracy of teledermatology 
is well supported by evidence in the literature [5-13]. 
Teledermatology services were found to have high rates 
of concordance to in-person evaluations and inpatient 
triaging consultations [14-16]. Clinical outcomes and 
skin-related quality of life measures are also similar for 
patients evaluated via teledermatology compared to in-
person visits [17-21]. Additionally, patients report high 
levels of satisfaction with the quality of care maintained 
through teledermatology services. A recent 2020 survey 
study in the Department of Dermatology at Yale School of 
Medicine found that patients were almost 50 times more 
likely than faculty to agree that the quality of care received 
during a teledermatology visit was equal to an in-person 
visit (odds ratio: 48.28, 95% confidence interval: 19.55-
128.40, p<0.001) [22]. 
Not only is the quality of care sustained through 
these technological innovations, but patients are 
also significantly more likely to maintain essential 
appointments which helps mitigate delayed diagnoses and 
treatment [23-31]. Telehealth patients also benefit from 
saving travel costs and time, which incurs financial savings 
from work absenteeism and transportation fees [23-30]. 
Several studies within the literature have found greater 
patient satisfaction with teledermatology [24,25,32-34]. 
According to a qualitative study on SAF teledermatology 
services among veterans in the Pacific Northwest, 66% of 
patients favored teledermatology over in-person visits, 
and 83% would recommend the service to others [33]. 
Some studies have reported clinical and financial benefits 
with telehealth services such as improved efficiency and 
remote patient access [28,34-36]. Our healthcare system 
financially benefits from these remote services as well. 
A cost analysis study for SAF teledermatology consults 
in underserved areas of Philadelphia demonstrated a 
reduction of in-person visits by 27% and of ER visits by 
3.3% [37]. Greater access to and consistency in care can 
help better manage dermatologic diseases at earlier and 
less financially burdensome phases of disease progression.
Despite the numerous benefits of teledermatology, 
prior to this pandemic, the most significant barrier to 
widespread teledermatology implementation was the 
lack of reliable systems for reimbursement and insurance 
coverage, particularly for the most vulnerable patients 
[30,38,39]. Obstacles hindering proactive policy changes 
included lack of universal payment through the Centers for 
Medicare and Medicaid Services (CMS), varying coverage 
for Medicaid patients across states, lack of universal 
private payer parity, and adoption and maintenance costs 
for individual systems [30]. These restrictions prevented 
many underserved populations from receiving much-
needed care, especially the elderly, disabled, and American 
Indian populations, for whom geographic and physical 
limitations pose major barriers to in-person care [30].
As COVID-19 cases continued to rise, the necessity for 
legislative changes to optimize access to care became 
overwhelming. On March 17, 2020, the CMS issued a 
1135 Waiver, which greatly expanded telehealth coverage 
by ensuring broad reimbursement for telehealth services, 
eliminating out-of-state licensing restrictions, and Health 
Insurance Portability and Accountability Act (HIPAA) 
compliance limitations [40-42]. During this public health 
emergency, Medicare reimbursed the same rate for a 
telehealth visit as it would for an in-person visit [43]. 
CMS also expanded telehealth coverage to all Medicare 
beneficiaries, not just those living in rural areas, and 
added 135 allowable services. Geographic restrictions on 
originating sites were also removed, allowing Medicare 
beneficiaries to receive telehealth services in the comfort 
and safety of their own homes [30,41,43]. 
For Medicaid, prior to the pandemic, states variably 
reimbursed for live-interactive telehealth services, and 
only 11 states reimbursed SAF services [30]. Currently, 
all 50 state Medicaid programs and that of Washington 
DC provide reimbursement for some form of live video 
telehealth services [39,42,44]. However, reimbursement 
for SAF technology and remote patient monitoring 
continues to lag, with only 18 and 21 states providing 
reimbursement, respectively [42,44]. Originating site 
restrictions for Medicaid coverage were also lifted, with 
27 states now explicitly and permanently allowing the 
home to serve as an eligible originating site under certain 
circumstances [42]. Additionally, 26 states and DC now 
reimburse telehealth services delivered in a school-based 
setting [42].
Across the nation, private insurance plans in 43 states 
and DC have changed their policies to expand telehealth 
coverage for patients [42]. Blue Cross Blue Shield (BCBS) 
of Massachusetts processed over a million telehealth 
claims within nine weeks of changing its policy to expand 
coverage [45]. These telehealth services are similarly 
reimbursed at the same rate as in-person visits for the 
duration of the public health emergency. Other insurance 
companies, such as Centene, are expanding access to 
telehealth for those in rural and underserved communities 
through disseminating smartphones and tablets to enable 
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patients to conduct telehealth visits [45]. BCBS of Arizona 
reported a 3,200% spike in telemedicine visits and 
enhanced benefit payments at 100% for telehealth and 
COVID-19 claims [45]. Blue Cross of Idaho estimated that 
their number of Telehealth claims between April 6th and 
April 19th, 2020 was 118 times their typical weekly average 
[45]. Some insurances have expanded access to virtual 
healthcare services and waived the member cost share 
for telehealth visits [45]. As such, patients face $0 out-of-
pocket costs. However, the majority of private insurance 
companies mark an end date, such as March or April 
2021, to these telehealth cost sharing waivers and other 
temporary expansions on telehealth coverage granted 
during the pandemic.
In the wake of these widespread changes to coverage 
and reimbursement, telehealth has rapidly expanded 
during the COVID-19 pandemic, with over 24.5 million 
out of 63 million Medicare beneficiaries receiving a 
telehealth service from March 2020 to mid-October 2020 
[46]. Telehealth private insurance claims have similarly 
increased by a reported 8,000% from April 2019 to April 
2020 [47]. Likewise, teledermatology has been expanded 
in an expedited fashion. Across 12 clinics affiliated with 
Massachusetts General Hospital, SAF asynchronous 
teledermatology accounted for 1 in 5 of all dermatology 
visits in April 2020 [48]. A web-based, global survey 
found that the use of teledermatology increased three-fold 
during the pandemic (26.1% vs. 75.2%), and that more 
than two thirds of respondents (68.6%) expect to continue 
teledermatology use in the future [49]. Unfortunately, 
many of the policy changes ensuring broad coverage 
for telehealth services covered under the pandemic are 
temporary, expanding only to the end of the public health 
emergency. To remain a viable modality of care, telehealth 
must be supported by ongoing state and federal legislation 
that ensures long-term Medicaid, Medicare, and private 
payer coverage at a reasonable fraction of in-person visits. 
For our most vulnerable and underserved populations, 
ongoing adoption of telemedicine may be vital to reducing 
disparities in access to care.
Many of the barriers to in-person care (i.e., low income 
and health literacy, insurance coverage, living in under-
resourced and underserved areas) disproportionately affect 
those who are already at a higher risk for dermatologic 
disorders. Minorities, people of low socioeconomic status, 
and the uninsured are reported to have greater incidences 
of atopic dermatitis and poorer prognoses for skin cancer, 
among other disparities in care [50]. These underserved 
populations may have become even more vulnerable 
during the pandemic as many free or student-run safety-
net clinics were forced to shut down [51]. 
Expanded telehealth services may help alleviate the 
healthcare burdens of some of these populations, giving 
them a fighting chance to equal access to care. While several 
articles have noted the potential for teledermatology to 
increase access for underserved patients since the onset of 
the pandemic [27,38,51,52], limited data exists regarding 
which populations have since specifically benefited. 
Beyond broadening overall access to dermatologic care, the 
recent rise in teledermatology has particularly improved 
access for rural and minority populations, as observed in a 
retrospective study comparing telehealth to in-person visits 
[53]. Additionally, teledermatology has been associated 
with decreased patient no-show rates when compared to 
in-person visits, especially in Black or African American, 
LatinX, and primary non-English speaking patients [31]. 
Teledermatology visits also served a greater percentage of 
Medicaid enrollees compared to clinic visits, however this 
may reflect the age-dependent differences in comfort levels 
with telehealth visits [31]. Although early data evaluating 
the impact of telehealth expansion has highlighted the 
potential role for this technology to improve health equity 
and minimize disparities, additional research must be done 
to fully understand how teledermatology has impacted all 
patient populations.
Most academic and private practices have adopted some 
form of teledermatology since the start of the COVID-19 
pandemic, mainly through increased implementation 
of both SAF asynchronous and live synchronous video 
appointments. Several other models of teledermatology 
have since emerged. At the start of the pandemic, 
recommendations for outpatient teledermatology practices 
included using existing platforms, prioritizing high-risk 
or urgent visits, and deferring non-essential visits [52]. 
Now, most ambulatory practices have transitioned to 
more hybrid practices, offering both in person and virtual 
visits, allowing dermatologists to focus virtual visits on 
specific skin conditions (i.e., acne, psoriasis, eczema, 
rashes, and rosacea) that have been shown to be more 
amenable to teledermatology [53,54]. In terms of inpatient 
dermatology, telehealth may be valuable in determining 
those who need an in-person visit versus those who can be 
successfully seen through telehealth, which can also help to 
conserve personal protective equipment [55]. Additionally, 
teledermatology can be utilized to triage inpatient consults 
to differentiate patients who need an isolation room, who 
can be managed outside of an isolation room, or who can 
be managed outside of a hospital [55,56].
While teledermatology holds great promise in increasing 
access to care for our most vulnerable populations, it 
is critical to consider and anticipate the ways in which 
telehealth may also exacerbate current disparities in order 
to address them. At the very least, telehealth services 
require access to a digital device (i.e., smartphone, 
computer, tablet), a reliable internet connection, and a 
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private space to conduct the visit. It is important to keep 
in mind that these require a certain level of technology 
literacy. The U.S. Federal Communications Commission 
reports demonstrate significant differences in household 
income between those with and without broadband 
internet, potentially widening the socioeconomic 
disparity in healthcare access during the pandemic [57]. 
Teledermatology specifically requires high-quality and 
well-positioned images with good lighting, which may 
further pose a strain on the patient and their internet 
usage [58]. Solutions that have been proposed include 
using more SAF technology compared to video visits, 
adding clinical hybrid appointments for patients without 
devices, and distributing refurbished devices [58]. Of note, 
smartphone ownership has become more ubiquitous in the 
U.S., with rates nationally increasing from an estimated 
35% in 2011 to 81% in 2019 [59]. Moreover, 70% of people 
with an income lower than $35,000 per year owned 
smartphones in 2019, demonstrating a trend decreasing 
the digital divide [59].
As telehealth adoption continues to grow and becomes 
more integral to how we deliver equitable quality care, other 
tools may also be implemented to optimize teledermatology 
services particularly in areas where a shortage of 
dermatology services exists. The implementation of “home 
dermoscopy” serves as a low-cost and simple method to 
improving image quality [60]. Artificial intelligence, 
such as a deep learning system (DLS), may also assist 
general practitioners and increase diagnostic accuracy of 
skin conditions. With current technology, DLS is able to 
assess images and leverage the patient’s medical history 
and demographics to identify several of the most common 
skin conditions referred for teledermatology consultations 
while also providing differential diagnoses [61]. With the 
advent of new technologies and increased adoption of 
telehealth services, the effect on malpractice insurance 
coverage remains unclear as policies vary by state and by 
insurance company. While the Federal Tort Claims Act 
provides malpractice liability coverage to all healthcare 
providers who work at federally qualified health centers, 
guidelines related to telehealth liability have not yet been 
outlined [62].
Future studies highlighting the impact of telehealth 
expansion are crucial for long-term legislative changes 
to occur and to effectively broaden coverage to those 
most vulnerable. These research studies need to be 
diversified to involve more minorities and underserved 
patient populations so that the data better elucidate true 
socioeconomic and racial disparities in dermatologic 
care. As the U.S. population becomes more diverse, the 
academic literature needs to reflect that shift to help bridge 
the gaps in dermatologic healthcare access. Continued 
advocacy efforts are equally as critical to promoting 
telehealth implementation and guaranteeing equitable 
access without compromising quality of care. 
Conclusion
Since March 2020, telehealth has drastically expanded 
across the nation with current literature supporting 
its efficacy, equitable quality and accuracy, and cost-
effectiveness. As the Medicare and Medicaid populations 
continue to rapidly expand amidst a relative shortage of 
physicians, the need to embrace technological innovation 
to improve care access, especially in rural and underserved 
areas, is greater than ever. However, until payers and 
policymakers implement more reliable and long-term 
methods for reimbursement, the full potential benefits and 
cost savings associated with teledermatology remain to be 
realized. It is imperative for policymakers to acknowledge 
the capability of technology in enhancing access and to 
formulate regulations through which these services can 
prudently assist routine dermatological care.
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